Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Loan Lam

Podiatrist, Foot & Ankle Surgery Tampa, FL Doctor of Podiatric Medicine

NPI 1386866077 CMS profile 199403

3609 Madaca Ln, Tampa, FL 33618

Open in the dashboard

General payments

$72,115

350 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Loan Lam of Tampa, FL is reported in the CMS Open Payments database as having received $72,115 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,711 117
2024 General $17,543 74
2023 General $1,771 37
2022 General $3,828 59
2021 General $696 16
2020 General $416 26
2019 General $1,148 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Loan Lam
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Loan Lam were reported at $46,711. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Loan Lam Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,148 $389 $118–$1,406 $163
2020 $416 $191 $62–$691 $114
2021 $696 $329 $104–$1,341 $132
2022 $3,828 $419 $125–$1,611 $149
2023 $1,771 $377 $128–$1,164 $160
2024 $17,543 $394 $134–$1,168 $164
2025 $46,711 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paratek Pharmaceuticals, Inc. $51,584 128 payments
  2. Organogenesis Inc. $8,665 52 payments
  3. Hartmann USA, Inc. $2,684 8 payments
  4. Kerecis Limited $1,693 5 payments
  5. Urgo Medical North America, LLC $1,394 20 payments
  6. LifeNet Health $1,365 7 payments
  7. ETS Wound Care LLC $1,012 10 payments
  8. Smith+Nephew, Inc. $867 42 payments
  9. KCI USA, Inc $657 10 payments
  10. Boston Scientific Corporation $598 11 payments
  11. Other $1,596 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,233 19 payments
  2. Travel and Lodging $20,455 45 payments
  3. Food and Beverage $10,338 278 payments
  4. Consulting Fee $5,085 5 payments
  5. Education $3 3 payments
Products named General payments · program years 2019–2025
  1. NUZYRA $51,584 128 payments
  2. NOVACHOR $4,541 9 payments
  3. Affinity $4,530 8 payments
  4. NuShield $2,850 5 payments
  5. ZETUVIT PLUS 10X10 P10 $2,671 7 payments
  6. Kerecis Omega3 SurgiClose $1,672 4 payments
  7. Kerecis Omega3 GraftGuide $1,672 4 payments
  8. Kerecis Omega3 Marigen Wound Care $1,642 3 payments
  9. Kerecis Omega3 Marigen Wound Care $1,642 3 payments
  10. Kerecis Omega3 Marigen Wound Care $1,642 3 payments
  11. Other $10,228 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

563

Median for Podiatry: 160

Drug cost

$272,286

Median for Podiatry: $2,368

Branded share of claims

9.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuzyra Omadacycline Tosylate Brand 37 $262,880
Pentoxifylline Generic 101 $2,510
Duloxetine Hcl Generic 90 $1,569
Cefdinir Generic 41 $1,132
Linezolid Generic 15 $846
Doxycycline Hyclate Generic 48 $825
Metronidazole Generic 14 $483
Methylprednisolone Generic 61 $465
Triamcinolone Acetonide Generic 11 $291
Levofloxacin Generic 41 $281

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$3,983,984

Of which drugs: $3,607,484

Medicare patients

83

Average age 74

Services billed

4,462

45 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Ischemic heart disease 51%
Chronic kidney disease 42%
Diabetes 41%
Depression 31%
Heart failure 30%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Amnio quad-core, per square centimeter Q4294 Office 16 1,748 $3,034,822

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $16,825
$16,825 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record